Table 3. Association between inhibition rates of each anti-cancer agent and clinical characteristics.

Characteristic	PatientsN = 100 N (%)	Cisplatininhibition rate %	Doctaxelinhibition rate %	Gemcitabine inhibition rate %	Irinotecanl inhibition rate %	Pemtrexed inhibition rate %
Age
>62	52 (52%)	45.20±20.78	44.79±21.64	46.31±22.23	42.60±23.08	51.21±22.77
≤62	48 (48%)	46.48±21.48	46.70±24.55	43.01±21.44	46.50±22.12	54.50±22.10
Sex
Male	73 (73%)	46.71±21.89	47.81±21.99	47.33±20.74	44.41±21.39	52.65±22.23
Female	27 (27%)	43.39±18.64	39.90±24.98	38.06±23.38	44.64±26.01	53.16±23.27
Histology
Adenocarcinoma	79 (79%)	48.71±19.80	44.48±22.33	45.89±21.53	42.66±21.67	54.11±23.02
Mucinous	11 (11%)	28.86±17.71	36.06±24.58	41.05±22.72	43.14±21.90	53.22±20.15
Signet ring cell	10 (10%)	50.46±12.87	47.32±25.05	39.63±24.24	37.55±31.13	55.62±22.95
Tumor Site
Distal	35 (35%)	52.20±19.38	47.84±22.92	41.67±20.12	42.28±24.22	49.22±23.55
Proximal	38 (38%)	41.86±19.31	39.52±21.90	48.04±23.13	42.60±23.11	57.61±19.91
Whole stomach	27 (27%)	46.81±20.07	45.04±23.65	43.87±22.19	41.35±20.35	55.37±24.51
Stage
I,II	37 (37%)	46.94±21.58	45.54±24.10	38.77±20.03	42.67±22.45	53.86±23.37
III, IV	63 (63%)	46.71±18.94	42.98±22.11	48.12±22.19	41.87±22.85	54.36±22.18
Histological grade
2	27 (27%)	46.83±22.49	45.73±22.27	50.07±20.02	43.44±22.71	55.17±19.31
3	44 (44%)	42.48±18.35	38.12±22.61	39.72±22.06	40.69±22.89	56.11±20.83
Mixed 2–3	29 (29%)	53.40±18.03	50.93±22.01	47.06±22.25	43.17±22.80	50.20±27.77
Lymph node metastasis
No	25 (25%)	48.82±23.19	48.81±24.53	39.01±22.98	42.80±22.84	52.53±20.81
Yes	75 (75%)	44.81±20.31	44.67±22.51	46.47±21.28	45.03±22.63	52.87±23.04

Data are expressed as mean ± standard deviation.